The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

Norbert Galldiks; Ian Law; Whitney B Pope; Javier Arbizu; Karl-Josef Langen

doi:10.1016/j.nicl.2016.12.020

The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

Norbert Galldiks, Ian Law, Whitney B Pope, Javier Arbizu, Karl-Josef Langen

Department of Clinical Medicine

65 Citations (Scopus)

60 Downloads (Pure)

Abstract

Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-enhanced MRI. However, the capacity of conventional MRI to differentiate tumor tissue from posttherapeutic effects following neurosurgical resection, chemoradiation, alkylating chemotherapy, radiosurgery, and/or immunotherapy may be limited. Metabolic imaging using PET can provide relevant additional information on tumor metabolism, which allows for more accurate diagnostics especially in clinically equivocal situations. This review article focuses predominantly on the amino acid PET tracers 11C-methyl-l-methionine (MET), O-(2-[18F]fluoroethyl)-l-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.

Original language	English
Journal	NeuroImage: Clinical
Volume	13
Pages (from-to)	386-394
Number of pages	9
ISSN	2213-1582
DOIs	https://doi.org/10.1016/j.nicl.2016.12.020
Publication status	Published - 2017

Keywords

Amino Acids
Brain Neoplasms/diagnostic imaging
Dihydroxyphenylalanine/analogs & derivatives
Humans
Methionine/analogs & derivatives
Positron-Emission Tomography/methods
Radiopharmaceuticals
Tyrosine/analogs & derivatives

Access to Document

10.1016/j.nicl.2016.12.020Licence: CC BY-NC-ND

The use of amino acid PET and conventional MRI for monitoring of brain tumor therapyFinal published version, 739 KBLicence: CC BY-NC-ND

Cite this

@article{4900b5b54f0645ef9e3535ca405e8b4b,

title = "The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy",

abstract = "Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-enhanced MRI. However, the capacity of conventional MRI to differentiate tumor tissue from posttherapeutic effects following neurosurgical resection, chemoradiation, alkylating chemotherapy, radiosurgery, and/or immunotherapy may be limited. Metabolic imaging using PET can provide relevant additional information on tumor metabolism, which allows for more accurate diagnostics especially in clinically equivocal situations. This review article focuses predominantly on the amino acid PET tracers 11C-methyl-l-methionine (MET), O-(2-[18F]fluoroethyl)-l-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.",

keywords = "Amino Acids, Brain Neoplasms/diagnostic imaging, Dihydroxyphenylalanine/analogs & derivatives, Humans, Methionine/analogs & derivatives, Positron-Emission Tomography/methods, Radiopharmaceuticals, Tyrosine/analogs & derivatives",

author = "Norbert Galldiks and Ian Law and Pope, {Whitney B} and Javier Arbizu and Karl-Josef Langen",

year = "2017",

doi = "10.1016/j.nicl.2016.12.020",

language = "English",

volume = "13",

pages = "386--394",

journal = "NeuroImage: Clinical",

issn = "2213-1582",

publisher = "Elsevier",

}

TY - JOUR

T1 - The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

AU - Galldiks, Norbert

AU - Law, Ian

AU - Pope, Whitney B

AU - Arbizu, Javier

AU - Langen, Karl-Josef

PY - 2017

Y1 - 2017

N2 - Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-enhanced MRI. However, the capacity of conventional MRI to differentiate tumor tissue from posttherapeutic effects following neurosurgical resection, chemoradiation, alkylating chemotherapy, radiosurgery, and/or immunotherapy may be limited. Metabolic imaging using PET can provide relevant additional information on tumor metabolism, which allows for more accurate diagnostics especially in clinically equivocal situations. This review article focuses predominantly on the amino acid PET tracers 11C-methyl-l-methionine (MET), O-(2-[18F]fluoroethyl)-l-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.

AB - Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-enhanced MRI. However, the capacity of conventional MRI to differentiate tumor tissue from posttherapeutic effects following neurosurgical resection, chemoradiation, alkylating chemotherapy, radiosurgery, and/or immunotherapy may be limited. Metabolic imaging using PET can provide relevant additional information on tumor metabolism, which allows for more accurate diagnostics especially in clinically equivocal situations. This review article focuses predominantly on the amino acid PET tracers 11C-methyl-l-methionine (MET), O-(2-[18F]fluoroethyl)-l-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.

KW - Amino Acids

KW - Brain Neoplasms/diagnostic imaging

KW - Dihydroxyphenylalanine/analogs & derivatives

KW - Humans

KW - Methionine/analogs & derivatives

KW - Positron-Emission Tomography/methods

KW - Radiopharmaceuticals

KW - Tyrosine/analogs & derivatives

U2 - 10.1016/j.nicl.2016.12.020

DO - 10.1016/j.nicl.2016.12.020

M3 - Review

C2 - 28116231

SN - 2213-1582

VL - 13

SP - 386

EP - 394

JO - NeuroImage: Clinical

JF - NeuroImage: Clinical

ER -

The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this